Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising ... to file for approval of Dupixent (dupilumab) in the new indication ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and ... (EoE), chronic spontaneous urticaria (CSU) and prurigo nodularis (PN), among others. Kymera intends to develop ...

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and ... (EoE), chronic spontaneous urticaria (CSU) and prurigo nodularis (PN), among others. Kymera intends to develop ...

Do not use if you are allergic to dupilumab or to any of the ingredients ... eosinophilic esophagitis, prurigo nodularis, or chronic obstructive pulmonary disease and also have asthma.

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT ... eosinophilic esophagitis, prurigo nodularis, or chronic obstructive pulmonary disease and also have asthma. Do ...